@abdelhamed012 HTN in ESRD: ? Why BB as first line and not RASi?
English
Shrey Tripathi
696 posts
Shrey Tripathi
@GotNephrons
Nephrologist @Richmond Nephrology Associates,Richmond,VA.
Virginia, USA Katılım Aralık 2011
231 Takip Edilen315 Takipçiler
Managing Blood Pressure in Dialysis Patients: A Summary of UK Clinical Practice Guideline
English
HTN in ESRD: ? Why BB as first line and not RASi? x.com/abdelhamed012/…
Abdelhamid Hamdy@abdelhamed012
Managing Blood Pressure in Dialysis Patients: A Summary of UK Clinical Practice Guideline
English
Shrey Tripathi retweetledi
Poor #oral #health associated with systemic #inflammation and unfavorable outcomes. What happens if #cirrhosis patient receives regular #dental #prophylaxis and #periodontal #maintenance?
jhep-reports.eu/article/S2589-… @VCU @VCU_Nephrology @VAResearch @JHEP_Reports
English
QME
QME
QME
podcasts.apple.com/us/podcast/thi…
Fish-Oil Supplementation and Cardiovascular Events in Patients Receiving Hemodialysis
#nephrology #medicine #meded
English
QME
QME
#nurse, #nurses, #nursing #RegisteredNurse #nurseEducation #nursingeducation #studentnurse
Great resources for ALL THE NURSES!
redcircle.com/shows/530ba8f2…
English
Nice collection podcasts.apple.com/us/podcast/gas… #gasto #gastroenterology podcasts.apple.com/us/podcast/gas…
English
Shrey Tripathi retweetledi
Simon Correa presenting on CV risk in CKD / CRIC @AHAScience @KidneyInCVD, “CKD matters…” CKD patients alone would be the 2nd most populous state in the union….@mvaduganathan @brendonneuen
English
Kidney disease pts get discriminated against for everything including life insurance. #kidney #insurance
English
Shrey Tripathi retweetledi
CMS has finalized coverage and payment for home dialysis for AKI.
English
Shrey Tripathi retweetledi
Check out @ASNKidney Podcast 🎧 on “Novel Therapies for IgA Nephropathy (IgAN)” with @Nephro_Sparks
#KidneyWk #Nephpearls
📌 Efficacy and Safety of Ravulizumab in IgAN: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial
📌 The Selective Endothelin Receptor Antagonist SC0062 in IgAN: A Randomized Double-Blind Placebo-Controlled Clinical Trial
📌 Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgAN
🎧 t.co/l3HvdljLZJ
Published in @JASN_News 👉🏼 journals.lww.com/jasn/pages/def…
Glenview, IL 🇺🇸 English
Shrey Tripathi retweetledi
